Australia's most trusted
source of pharma news
Posted 24 October 2024 AM
Just three months into the role, an Australian CEO of an American pharma has repositioned the company to grow its commercial portfolio, signing a global distribution deal.
Dr Mike Exton became CEO of Lexicon Pharmaceuticals in July, after spending 13 years at Novartis, finishing up there as Global Cardiovascular Therapeutic Area Head. In August the company announced it would optimise promotional efforts for its sotagliflozin portfolio, which includes heart-failure drug Inpefa along with diabetes drug Zynquista.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.